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as a phosphate binder. Results regarding the change in
serum bicarbonate concentration after discontinuation ofTransient decrease of serum
calcium carbonate and during treatment with Sevelamer
HCl are illustrated in Table 1. At the end of the two-bicarbonate levels with
week washout period, the serum bicarbonate decreased
by a mean of 1.9 mmol/L, from 20.1 6 2.6 to 18.2 6 3.1Sevelamer hydrochloride
mmol/L. A further reduction to 17.3 6 3.2 mmol/L was
observed in the first week of treatment with Sevelameras the phosphate binder
HCl, but bicarbonate levels remained stable during the
To the Editor: Calcium carbonate is widely used as a following weeks of treatment and during the two-week
phosphate binder: it reduces phosphate absorption by the washout after discontinuation of Sevelamer HCl. Analysis
intestine and it ameliorates metabolic acidosis, but in- of variance (ANOVA) failed to detect significant varia-
creases plasma calcium concentrations. The limitations tions of bicarbonate levels. However, the decrease ob-
of currently available aluminum-based and calcium-based served at three weeks after discontinuation of calcium
phosphate binding agents and the impact of uncontrolled carbonate was significant (P , 0.05) at the individual post-
phosphorus levels on the morbidity and mortality of pa- test when compared to baseline values.
tients with kidney disease [1] have prompted the search Acidemia in patients with chronic renal failure should
for new therapeutic approaches of hyperphosphatemia be avoided because bone buffering of some of the excess
in dialysis patients. Sevelamer hydrochloride (RenaGelt; hydrogen ions is associated with the release of calcium
GelTex Pharmaceuticals, Waltham, MA; distributed by and phosphate from bone [4]. Preventing this change may
Genzyme Corporation, Cambridge, MA, USA) is a novel minimize the degree of negative calcium balance and pre-
calcium- and aluminum-free polymer [cross-linked poly- vent or delay the progression both of osteopenia and of
allylamine hydrochloride)]. It contains multiple amines hyperparathyroid bone disease. In this short term study,
(40% amine hydrochloride) separated by one carbon from no clinically significant changes in bicarbonate levels could
the polymer backbone and it is not absorbed by the intes- be observed after discontinuation of calcium carbonate
tine. These amines are partially protonated and interact and during treatment with Sevelamer HCl in hemodialysis
with phosphate molecules through ionic and hydrogen patients. However, a transient decrease was observed in
bonding, therefore reducing phosphate absorption and the first three weeks after discontinuation of calcium car-
lowering serum phosphate concentration [2]. bonate. Such a reduction appears to be dependent on the
Previous studies showed a trend toward lowered serum withdrawal of calcium carbonate (and the a consequent
bicarbonate concentrations during administration of Seve- reduced intake of alkali) rather than on treatment with
lamer HCl that were not statistically significant [3]. We Sevelamer HCl. Bone buffering could have prevented fur-
studied the effects of substituting Sevelamer HCl for cal- ther decreases of bicarbonate levels. This hypothesis un-
cium carbonate on metabolic acidosis in 16 clinically stable derscores the need for further studies on acid-base balance
chronic hemodialysis patients. Following a two-week during long-term treatment with Sevelamer HCl, in pa-
phosphate binder washout period, patients previously tients who discontinue calcium salts.
treated with calcium carbonate at the mean (6 SD) dose
Maurizio Gallieni, Mario Cozzolino, and Diego Brancaccioof 3.2 6 1.1 g/day were treated with Sevelamer HCl for
Milano, Italy6 weeks. The treatment period was followed by two addi-
tional weeks of washout. Correspondence to Maurizio Gallieni, M.D., Renal Unit—Azienda
Ospedaliera San Paolo via A. di Rudinı`, 8-20142 Milano, ItalyStarting doses of Sevelamer HCl (capsules, 403 mg)
E-mail: gallieni@iol.it
varied depending on the patient’s degree of hyperphos-
phatemia at the end of the first washout period. Patients REFERENCES
with serum phosphate levels between 5.5 and 6.5 mg/dL
1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Associationreceived 5 capsules per day (11212 capsules with meals);
of serum phosphorus and calcium 3 phosphate product with mortality
between 6.5 and 7.5 mg/dL, 7 capsules per day (11313); risk in chronic hemodialysis patients: A national study. Am J Kidney
Dis 31:607–617, 1998and over 7.5 mg/dL, 9 capsules per day (11414). All
2. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbedpatients were treated with a bicarbonate concentration of calcium- and aluminum-free phosphate binder, lowers serum phos-
34 mmol/L in the dialysis fluid, and the duration of dialysis phorus and parathyroid hormone. The RenaGel Study Group. Kidney
Int 55:299–307, 1999was 3 to 4 hours (mean 6 SD: 3.7 6 0.5 hours).
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a significant reduction of serum phosphate (from 7.3 6 hydrochloride] (Renagel): A non calcemic phosphate binder for the
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Kidney Int 47:1816–1832, 1995P , 0.001) was observed, confirming its excellent efficacy
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Table 1. Weekly determinations of predialysis serum bicarbonate levels (mean 6 standard deviation) during the study
Wash-out Treatment with Sevelamer HCl Wash-out
Week w.o.22 w.o.21 0 Rx 1 Rx 2 Rx 3 Rx 4 Rx 5 Rx 6 w.o.7 w.o.8
Mean 20.05 18.9 18.2 17.3a 18.6 18.3 18.25 19.1 19.0 20.4 19.2
SD 2.56 3.15 3.07 3.15 2.6 3.4 3.1 3.2 2.7 2.55 3.0
Abbreviations are: w.o., wash-out; Rx, treatment with Sevelamer HCl (begun at time 0).
a P , 0.05 by the uncorrected ANOVA post-test vs. baseline values
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